# PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

> **NCT00454779** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 113 (actual)

## Conditions studied

- Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Panitumumab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00454779
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-01
- **Primary completion:** 2012-06-11
- **Final completion:** 2014-01-01
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454779, "PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00454779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*